Amitriptyline (AMI) is a traditional
tricyclic antidepressant that has been proven to exhibit
neuroprotective effects in various
neurological disorders. However, the underlying mechanism by which AMI attenuates
lidocaine-induced neurotoxicity remains poorly understood.
Brain-derived neurotrophic factor (
BDNF) is an essential
neurotrophin to neuronal development and survival in the brain, and recent studies have suggested that
BDNF plays an important role in mediating
lidocaine-induced neurotoxicity. The present study was performed to evaluate the protective effect of AMI against the neurotoxicity induced by
lidocaine and to explore the role of
BDNF-dependent autophagy in this process. The data showed that AMI pretreatment alleviated
lidocaine-induced neurotoxicity, as evidenced by the restoration of cell viability, normalization of cell morphology, and reduction in the cell apoptosis index. In addition, autophagy inhibitor
3-methyladenine (3-MA) had a protective effect similar to that of AMI, but autophagy activator
rapamycin eliminated the protective effect of AMI by suppressing mTOR activation. Moreover, at the molecular level, we found that AMI-mediated autophagy was involved in the expression of
BDNF. The overexpression of
BDNF or application of exogenous recombinant
BDNF significantly suppressed autophagy and protected SH-SY5Y cells from apoptosis induced by Lido, whereas the neuroprotection of AMI was abolished by either knockdown of
BDNF or use of a
tropomyosin-related
kinase B (TrkB) inhibitor ANA-12 in SH-SY5Y cells. Overall, our findings demonstrated that the protective effect of AMI against
lidocaine-induced neurotoxicity correlated with inhibition of autophagy activity through upregulation of
BDNF expression.